Important: VAERS reports alone cannot determine if a vaccine caused an adverse event. Reports may contain incomplete, inaccurate, or unverified information. Correlation does not equal causation.
A comprehensive, plain-English breakdown of the 2026 CDC immunization schedule — from birth through 65 and older — including this year's updated COVID boosters, expanded RSV recommendations, Penbraya for adolescents, and the streamlined PCV20 pathway for adults.
The recommended immunization schedule in the United States is reviewed and updated each year by ACIP, a panel of medical and public health experts, and then adopted by the CDC. The schedule is organized by age because the immune system, disease risk, and exposure change dramatically across a lifetime. Infants need protection against diseases that are most dangerous in the first months of life; adolescents receive vaccines timed to precede new exposures; and older adults receive vaccines targeting conditions that become more severe with age.
Below is a stage-by-stage walkthrough of the 2026 schedule. For the compact reference table with direct links to each vaccine's adverse event data, use the vaccine schedule reference page.
The first two years of life contain the densest part of the schedule because maternal antibodies fade and infants become vulnerable to serious infections. The series begins at the hospital and continues through well-child visits.
Because so many doses are given during infancy, this age group generates a meaningful share of reports in passive surveillance systems. Our pediatric VAERS analysis explains why raw report counts for young children must be interpreted in the context of how many doses are administered.
Toddlers and preschoolers receive booster doses that lock in long-term immunity ahead of school entry. Around 15–18 months children get a 4th DTaP dose, and between 4 and 6 years they receive their final DTaP and polio doses along with the 2nd MMR and 2nd varicella doses. Annual influenza vaccination continues every year. Most states require proof of these vaccines for kindergarten — see our guide to state vaccine requirements for 2026.
The pre-teen visit around ages 11–12 is a major milestone. It typically includes:
A notable 2026 development is Penbraya, the first pentavalent meningococcal vaccine, which combines protection against serogroups A, C, W, Y, and B in a single product. For adolescents and young adults who would otherwise receive separate MenACWY and MenB shots, Penbraya can reduce the number of injections. Older teens and college-bound students often also receive MenB (serogroup B) vaccination based on shared clinical decision-making.
Adults in this range need an annual influenza vaccine, a Td or Tdap booster every 10 years, and the updated annual COVID-19 vaccine. HPV vaccination is recommended through age 26 (and available through 45 based on shared decision-making). Adults who missed childhood vaccines — for MMR, varicella, or hepatitis B — should catch up. Pregnancy adds specific recommendations: Tdap during every pregnancy (weeks 27–36), influenza in any trimester, and seasonal RSV vaccination at 32–36 weeks to protect the newborn.
At age 50, adults become eligible for Shingrix, a 2-dose recombinant vaccine that is highly effective at preventing shingles and its painful complication, postherpetic neuralgia. Annual influenza and updated COVID-19 vaccination continue. Adults with certain health conditions may also be recommended pneumococcal and hepatitis B vaccination earlier than 65.
Older adults face greater risk from respiratory infections, so the 2026 schedule emphasizes:
Because seniors receive many vaccines and have higher baseline rates of illness, they account for a disproportionate share of serious reports in passive surveillance. Our analysis of the 65+ age group unpacks why report counts alone can be misleading for older adults.
Parents sometimes question why the infant schedule is so dense. The medical rationale is straightforward: infants are most vulnerable to many infectious diseases during their first year of life, when maternal antibodies are waning and their own immune systems are still developing. Delaying vaccines leaves children unprotected during their highest-risk period.
Key facts about the childhood schedule:
Every vaccine in the schedule has an expected side effect profile — most commonly soreness at the injection site, mild fever, and fatigue that resolve within a few days. VaccineWatch maintains plain-language side effect guides drawn from VAERS data, including COVID-19, influenza, MMR, HPV, Tdap, and shingles. Browse the complete collection on the vaccine side effects hub.
Remember that VAERS is a passive, self-reporting system. A report means an event happened after vaccination, not that the vaccine caused it. For more on how to interpret this data responsibly, see our denominator problem analysis.